Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AxoGen Inc AXGN

Technology Scientific & Technical Instruments
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance... see more

Recent & Breaking News (NDAQ:AXGN)

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

GlobeNewswire 18 hours ago

Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 24, 2025

Axogen, Inc. To Host Analyst & Investor Day on March 4th

GlobeNewswire February 25, 2025

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

GlobeNewswire February 25, 2025

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

GlobeNewswire February 11, 2025

Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 3, 2025

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 10, 2025

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

GlobeNewswire January 10, 2025

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

GlobeNewswire November 7, 2024

Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024

GlobeNewswire October 24, 2024

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

GlobeNewswire September 6, 2024

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

GlobeNewswire September 3, 2024

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

GlobeNewswire August 13, 2024

Axogen, Inc. Announces New Leadership Appointments

GlobeNewswire August 8, 2024

Axogen, Inc. Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

GlobeNewswire July 23, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire July 1, 2024

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix(TM)

GlobeNewswire June 24, 2024

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

GlobeNewswire May 28, 2024

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

GlobeNewswire May 16, 2024